Welcome to our dedicated page for Moleculin Biotec SEC filings (Ticker: MBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Moleculin Biotech, Inc. (Nasdaq: MBRX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central to understanding Moleculin’s progress as a Phase 3 clinical stage pharmaceutical company focused on hard-to-treat tumors and certain viral infections.
Through Moleculin’s Form 8-K current reports, investors can review material events such as clinical and scientific milestones, corporate presentations, patent developments, financing transactions and listing-related communications. Recent 8-K filings have furnished press releases on positive Phase 1 results for WP1066 in pediatric recurrent malignant brain tumors, updates on enrollment and unblinding plans for the pivotal MIRACLE Phase 2B/3 AML trial of Annamycin plus cytarabine (AnnAraC), and independent assessments of Annamycin’s cardiotoxicity profile. Other 8-Ks describe grant-funded and investigator-initiated research agreements for Annamycin in pancreatic cancer and glioblastoma multiforme, as well as patent grants for preliposomal Annamycin lyophilizates.
Moleculin’s filings also document capital markets and listing matters, including notices from Nasdaq regarding bid price and stockholders’ equity requirements, the company’s responses and appeal plans, and the implementation of a 1-for-25 reverse stock split with continued trading under the MBRX symbol. Additional filings cover warrant exercises, special stockholder meeting results and approvals related to equity issuances.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are paired with AI-powered summaries that highlight key points, such as clinical trial status, regulatory designations, patent protections and financing terms. Users can quickly scan 8-Ks and related reports to understand how Moleculin is advancing Annamycin, WP1066 and WP1122, how it is managing its Nasdaq listing, and how corporate actions may affect shareholders. This page also helps surface insider and governance-related information when reported through the company’s SEC submissions.
Moleculin Biotech, Inc. is asking shareholders to approve three proposals at a Special Meeting on
The proxy also asks shareholders to approve a corporate name change to Moleculin Inc. and to authorize adjournment of the meeting if additional solicitation of proxies is needed. Shares outstanding were 4,933,110 as of February 20, 2026, and the company states that full cash exercise of the Warrants at the initial exercise price would yield
Moleculin Biotech entered into warrant exercise inducement agreements with holders of existing warrants to buy up to 2,122,652 shares at
In return, Moleculin will issue new Series H Inducement Warrants to purchase up to 6,367,956 shares, equal to 300% of the exercised shares. These warrants will have a five-year term and an exercise price per share equal to the lesser of
Moleculin Biotech, Inc. filed a current report to make investors aware that it is using an updated corporate presentation. The company states that this presentation is posted on its website and is included as Exhibit 99.1.
The company clarifies that the information in this presentation is being furnished under a disclosure item and is not considered "filed" under securities laws, unless a future document specifically incorporates it by reference. This distinction affects how the information is treated for legal and liability purposes.
Moleculin Biotech updated progress on its pivotal Phase 2B/3 MIRACLE trial of Annamycin plus cytarabine in second-line relapsed/refractory AML. As of February 10, 2026, 35 subjects have been treated, with another 11 in screening or identified, targeting 45 subjects for the first data unblinding.
In the first 30 treated subjects with blinded efficacy data, the company reports a preliminary composite complete remission (CRc) rate of 40%, made up of 30% complete remission (CR) and 10% CR with partial hematologic recovery (CRh). Moleculin highlights that roughly 35% of treated subjects had failed prior venetoclax regimens and that current blinded CR rates are described as 67% higher than historical cytarabine-alone HiDAC trials at about 17–18% CR.
The company continues to report an absence of cardiotoxicity for Annamycin based on safety data from 90 prior trial subjects and expects to reach 45 treated MIRACLE subjects in the first quarter of 2026, with unblinding of the first 45 subjects’ efficacy data anticipated in late second quarter 2026, followed by additional unblindings as Part A of the trial completes.
Moleculin Biotech reported that the Japan Patent Office issued a notice of allowance for Patent Application No. 2021-577862, titled “METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN.” A patent from this application is expected to be granted in Japan in the coming months.
The allowed claims cover proprietary methods for reconstituting and preparing liposomal Annamycin from a preliposomal lyophilizate under controlled temperature conditions, targeting precise concentrations for intravenous use and consistent dosing and stability. This Japanese protection complements existing U.S. and European patent coverage for Annamycin.
Annamycin, also known as naxtarubicin, is Moleculin’s lead anthracycline drug candidate in Phase 3 development for relapsed or refractory acute myeloid leukemia, with Fast Track Status and multiple Orphan Drug Designations in the U.S. and Europe.
Moleculin Biotech, Inc. stockholders approved the issuance of up to 2,610,823 shares of common stock upon exercise of certain warrants issued on December 11, 2025. The warrant-related Nasdaq Proposal passed with 578,385 votes for, 68,176 against and 3,444 abstentions, with 546,307 broker non-votes.
Stockholders did not approve changing the company’s name to Moleculin Inc., because the vote did not reach the required majority of all outstanding shares, even though 1,124,921 voted for, 67,441 against and 3,950 abstained. They also approved a potential adjournment to solicit additional proxies if needed.
Moleculin Biotech, Inc. filed a current report to note that it is using a new corporate presentation for investors and other audiences. The presentation is posted on the company’s website and is included as Exhibit 99.1 to the report. The company specifies that this material is being furnished under a disclosure item for informational purposes and is not deemed filed under securities laws unless later specifically incorporated by reference.
Moleculin Biotech, Inc. filed a current report to furnish a press release about new safety information for its investigational drug Annamycin. The company states that an independent assessment confirmed no cardiotoxicity of Annamycin in 90 subjects, addressing an important safety consideration related to potential effects on the heart. The press release is included as Exhibit 99.1 and is furnished under Item 7.01, meaning it is provided for information purposes and is not treated as filed under securities law requirements.
Moleculin Biotech, Inc. filed a current report to furnish a press release dated January 12, 2026. The release states that the company is accelerating its outlook into 2026, with its first pivotal trial unblinding described as on track.
The press release also highlights global trial expansion and multiple clinical programs that are externally and investigator-initiated trial (IIT) funded. The information is furnished under a Regulation FD disclosure item and is not deemed filed under the federal securities laws unless later specifically incorporated by reference.
Moleculin Biotech, Inc. reported that it has regained compliance with Nasdaq’s continued listing standards. The company had previously been notified in May 2025 that it failed to meet Nasdaq Listing Rule 5550(b)(1), which requires at least